Literature DB >> 12830403

Randomized comparison of artesunate and quinine in the treatment of severe falciparum malaria.

Paul N Newton1, Brian J Angus, Wirongrong Chierakul, Arjen Dondorp, Ronatrai Ruangveerayuth, Kamolrat Silamut, Pramote Teerapong, Yupin Suputtamongkol, Sornchai Looareesuwan, Nicholas J White.   

Abstract

A randomized, open-label comparison of artesunate and quinine was conducted in 113 adults with clinically severe falciparum malaria in western Thailand. Mortality was 12% with artesunate and 22% with quinine treatment (relative risk, 0.53; 95% confidence interval, 0.23-1.26; P=.22). Multiple logistic regression analysis found admission plasma lactate level, Glasgow Coma Scale score, and total serum bilirubin level to be independent risk factors for death. Coma recovery and times to normalize plasma lactate levels were similar, but the parasite clearance time was much shorter among artesunate-treated patients (P=.019). Fewer patients became hypoglycemic during artesunate therapy (10%) than during quinine therapy (28%) (P=.03). Artesunate is at least as effective as quinine in the treatment of adults with severe malaria. Larger trials are required to determine whether mortality is reduced among patients treated with artesunate.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12830403     DOI: 10.1086/375059

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  29 in total

Review 1.  Neurological syndromes and the traveller: an approach to differential diagnosis.

Authors:  J N Day; D G Lalloo
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-03       Impact factor: 10.154

Review 2.  Malaria: an update on treatment of adults in non-endemic countries.

Authors:  Christopher J M Whitty; David Lalloo; Andrew Ustianowski
Journal:  BMJ       Date:  2006-07-29

3.  Pharmacokinetics of oral doxycycline during combination treatment of severe falciparum malaria.

Authors:  Paul N Newton; Jean-François Chaulet; Alan Brockman; Wirongrong Chierakul; Arjen Dondorp; Ronatrai Ruangveerayuth; Sornchai Looareesuwan; Cyril Mounier; Nicholas J White
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

4.  The pharmacokinetics of intravenous artesunate in adults with severe falciparum malaria.

Authors:  Paul N Newton; Karen I Barnes; Peter J Smith; Alicia C Evans; Wirongrong Chierakul; Ronatrai Ruangveerayuth; Nicholas J White
Journal:  Eur J Clin Pharmacol       Date:  2006-11-07       Impact factor: 2.953

Review 5.  Artesunate versus quinine for treating severe malaria.

Authors:  David Sinclair; Sarah Donegan; Rachel Isba; David G Lalloo
Journal:  Cochrane Database Syst Rev       Date:  2012-06-13

6.  Probability of emergence of antimalarial resistance in different stages of the parasite life cycle.

Authors:  Wirichada Pongtavornpinyo; Ian M Hastings; Arjen Dondorp; Lisa J White; Richard J Maude; Sompob Saralamba; Nicholas P Day; Nicholas J White; Maciej F Boni
Journal:  Evol Appl       Date:  2009-02       Impact factor: 5.183

Review 7.  Malaria: severe, life-threatening.

Authors:  Aika Amy Anita Omari; Paul Garner
Journal:  BMJ Clin Evid       Date:  2007-07-01

8.  Artemether bioavailability after oral or intramuscular administration in uncomplicated falciparum malaria.

Authors:  Kamolrat Silamut; Paul N Newton; Paktiya Teja-Isavadharm; Yupin Suputtamongkol; Duangsuda Siriyanonda; Maneerat Rasameesoraj; Sasithon Pukrittayakamee; Nicholas J White
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

9.  Intravenous artesunate versus intravenous quinine in the treatment of severe falciparum malaria: a retrospective evaluation from a UK centre.

Authors:  Marcus Eder; Hugo Farne; Tamsin Cargill; Aula Abbara; Robert N Davidson
Journal:  Pathog Glob Health       Date:  2012-07       Impact factor: 2.894

10.  Geographical concentration of falciparum malaria treated in the UK and delay to treatment with artesunate in severe cases: an observational study.

Authors:  Claire Broderick; Philip Friend; Valerie Smith; Marie Blaze; Philip Gothard; Peter L Chiodini; Christopher Jm Whitty
Journal:  BMJ Open       Date:  2012-11-12       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.